Noor Ul Ain Rehman
Sun, May 10, 2026 astatine 6:13 PM CDT 2 min read
Erasca, Inc. (NASDAQ:ERAS) besides received a standing update from H.C. Wainwright connected April 28. The steadfast maintained a Buy standing connected the banal with a $20 terms target, with the standing coming aft the institution reported preliminary Phase 1 information for ERAS-0015. H.C. Wainwright told investors successful a probe enactment that portion the information shows a “clear step-up successful aboriginal efficacy” comparative to the pre-readout bar, particularly successful lung cancer, it is important to enactment that ERAS-0015’s information illustration is “directionally favorable but not without caveats.” It added that the dataset is “not afloat clean”, and this “introduces hostility with the different benign information communicative and raises questions astir attribution and reporting consistency”.
Erasca, Inc. (NASDAQ:ERAS) is simply a clinical-stage precision oncology institution with a absorption connected the discovery, development, and commercialization of therapies for patients with RAS/MAPK pathway-driven cancers. The institution has assembled a wholly owned oregon controlled RAS/MAPK pathway-focused pipeline that comprises modality-agnostic programs.
While we admit the imaginable of ERAS arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich successful 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey connected Google News.

5 days ago
8





English (CA) ·
English (US) ·
Spanish (MX) ·